Treatment strategies for locally recurrent rectal cancer
A partir d'une revue de la littérature, cette étude évalue l'efficacité des différentes stratégies pour traiter un cancer du rectum récidivant localement
The evolution of rectal cancer treatment over the last two decades including advances in surgical technique (total mesorectal excision), the advent of pre-operative MRI staging, and judicious use of neoadjuvant therapy has resulted in a significant reduction in local recurrence of approximately 5–10%. However, the effects of locally recurrent rectal cancer (LRRC) can be devastating, with a median survival of approximately 8 months and a multitude of distressing symptoms including pelvic pain, rectal bleeding and mucous discharge, all of which can adversely affect a patient's quality of life.